SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs(India) - Quaterly Results

27 May 2024 Evaluate
The sales is pegged at Rs. 391.36 millions for the March 2024 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 432.83 millions during the year-ago period.The Company's Net profit for the March 2024 quarter have declined marginally to Rs. 36.42  millions as against Rs. 51.29 millions reported during the corresponding quarter ended.Operating profit for the quarter ended March 2024 decreased to 61.13 millions as compared to 81.19 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 391.36 432.83 -9.58 1315.99 1177.84 11.73 1315.99 1177.84 11.73
Other Income 8.96 14.32 -37.43 61.89 45.98 34.60 61.89 45.98 34.60
PBIDT 61.13 81.19 -24.71 265.06 217.71 21.75 265.06 217.71 21.75
Interest 4.45 4.07 9.34 19.08 9.85 93.71 19.08 9.85 93.71
PBDT 56.68 77.12 -26.50 245.98 207.86 18.34 245.98 207.86 18.34
Depreciation 4.10 3.73 9.92 12.44 13.37 -6.96 12.44 13.37 -6.96
PBT 52.58 73.39 -28.36 233.54 194.49 20.08 233.54 194.49 20.08
TAX 16.16 22.10 -26.88 57.79 37.32 54.85 57.79 37.32 54.85
Deferred Tax 3.01 1.70 77.06 -5.86 -4.66 25.75 -5.86 -4.66 25.75
PAT 36.42 51.29 -28.99 175.75 157.17 11.82 175.75 157.17 11.82
Equity 160.82 155.82 3.21 160.82 155.82 3.21 160.82 155.82 3.21
PBIDTM(%) 15.62 18.76 -16.73 20.14 18.48 8.97 20.14 18.48 8.97

Kilitch Drugs(India) Share Price

135.05 -0.05 (-0.04%)
20-Apr-2026 14:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.15
Dr. Reddys Lab 1234.30
Cipla 1232.95
Zydus Lifesciences 938.40
Lupin 2329.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×